抗凝技术在危重症肾脏替代治疗应用的中国专家共识(2023年版)  

Chinese expert consensus on the application of anticoagulant technology in renal replacement therapy for critical patients(2023)

作　　者：共识专家组 梅长林 丁峰[3] Expert Consensus Working Group;Mei Changlin;Ding Feng(不详;Department of Nephrology,Changzheng Hospital Affiliated to Naval Medical University,Shanghai 200003,China;Department of Nephrology,the Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,Shanghai 200011,China)

机构地区：[1]不详 [2]海军军医大学附属长征医院肾脏科,上海200003 [3]上海交通大学医学院附属第九人民医院肾脏科,上海200011

出　　处：《中华肾脏病杂志》2023年第2期155-164,共10页Chinese Journal of Nephrology

摘　　要：安全有效的抗凝是危重症患者肾脏替代治疗(renal replacement therapy,RRT)成功的关键,然而目前仍缺乏针对危重症患者RRT的抗凝指导和推荐。该共识由国内肾脏病、危重医学以及检验医学专家共同讨论制定,结合该领域的最新文献和国内外指南,介绍抗凝剂的作用机制和抗凝剂的选择,旨在指导和规范危重症患者RRT中的抗凝技术应用。Safe and effective anticoagulation is the key for successful renal replacement therapy(RRT)in critical patients.However,there is still a lack of guidance and recommendation on anticoagulation for RRT in critical patients.Combined with the latest literature and guidelines in this field,this consensus was jointly formulated by nephrologists,intensive care and clinical laboratory specialists in China.It introduces the mechanisms of anticoagulants and the selection of anticoagulants,and aims to guide and standardize the application of anticoagulation technology in RRT for critical patients.

关 键 词：血液凝固 抗凝血药 危重病 肾替代疗法 专家共识 

分 类 号：R459.5[医药卫生—治疗学]